期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

结直肠癌生物学基础及其靶点药物治疗研究进展 被引量：1

原文传递
导出
摘要 随着分子生物学和免疫学等学科的发展．肿瘤治疗出现了许多新型治疗靶点，其相关药物也进入了临床试验阶段。本文就近年来结直肠癌（colorectal cancer，CRC）的生物学基础及其相关靶点药物治疗的研究进展作一综述。
作者 黄玉宝 卿三华 叶长生
机构地区 南方医科大学附属南方医院普通外科
出处 《中华胃肠外科杂志》 CAS 2008年第3期294-296,共3页 Chinese Journal of Gastrointestinal Surgery
关键词 生物学基础 治疗靶点 药物治疗 结直肠癌 分子生物学 肿瘤治疗 临床试验 相关药物
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ , randomized trim comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003,21:60-65.
  • 2Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004,350:2335-2342.
  • 3Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem, 2005,6:550-557.
  • 4Capdevila J, Saura C, Macarulla T, et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. EJSO, 2007,33 : S24-S34.
  • 5Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermalgrowth factor receptor. J Clin Oncol, 2004,22 : 1201-1208.
  • 6Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus ifinotecan in irinotecan- refractory metastatic eolorectal cancer. N Engl J Med, 2004,351r337-345.
  • 7Cho CD, Fisher GA, Halsey J, et al. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies, Invest New Drugs, 2006,24. 117-123.
  • 8Kuo T, Cho CD, Halsey J, et al. Phase Ⅱ study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol, 2005,23 : 5613-5619.
  • 9Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008,26:374-379.
  • 10Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 2001,93: 1062-1074.

同被引文献12

  • 1Saif MW.Targeted agents for adjuvant therapy of colon cancer.Clin Colorectal Cancer,2006,6(1):46-51.
  • 2Willett CG,Duda DG,Czito BG,et al.Targeted therapy in rectal cancer.Oncology(Williston Park),2007,21(9):1055-1065.
  • 3Chu EC,Chai J,Ahluwalia A,et al.Mesalazine downregulates c-Myc in human colon cancer cells.A key to its chemopreventive action? Aliment Pharmacol Ther,2007,25(12):1443-1449.
  • 4Binion DG,Otterson MF,Rafiee P.Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.Gut,2008,57(11):1509-1517.
  • 5Gartel AL,Shchors K.Mechanisms of c-Myc-mediated transcriptional repression of growth arrest genes.Exp Cell Res,2003,283(1):17-21.
  • 6Sansom OJ,Meniel VS,Muncan V,et al.Myc deletion rescues Apc deficiency in the small intestine.Nature,2007,446(7136):676-679.
  • 7Wilkins JA,Sansom OJ.C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine.Cancer Res,2008,68(13):4963-4966.
  • 8Díaz-Rubio E.Vascular endothelial growth factor inhibitors in colon cancer.Adv Exp Med Biol,2006,587:251-275.
  • 9Nygren P,Sφrbye H,Osterlund P,et al.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab:an Acta Oncologica expert report.Acta Oncol,2005,44(3):203-217.
  • 10Abaza MS,Al-Saffar A,Al-Sawan S,et al.c-Myc Antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs.Tumour Biol,2008,29(5):287-303.

引证文献1

二级引证文献3

中华胃肠外科杂志
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部